PT
● MODULE 05 / 20
Cholinergic Drugs & Neuromuscular Transmission
Use receptor location to predict parasympathetic effects, blockade and neuromuscular paralysis.
Quick revision ↓ Medical Dictionary
FULL CHAPTER EXPLANATION
Deep Learning — Module 05
Read this section in sequence. It moves from drug targets to therapeutic effects, adverse reactions and safe use.
01
The cholinergic map
Acetylcholine activates nicotinic receptors in autonomic ganglia and skeletal neuromuscular junctions, and muscarinic receptors at many parasympathetic effector organs. Sympathetic sweat glands are a useful cholinergic exception. Muscarinic stimulation can slow the heart, constrict pupils and bronchi, and increase secretions and gut motility. Nicotinic effects depend on whether the receptor is neuronal or muscular. A receptor map predicts both intended effects and toxicity more reliably than a list of drug names.
02
Agonists and enzyme inhibitors
Bethanechol directly stimulates muscarinic receptors and illustrates effects on bladder and gut smooth muscle, but mechanical obstruction must be excluded. Pilocarpine increases secretions and can constrict the pupil. Neostigmine and pyridostigmine inhibit acetylcholinesterase, increasing acetylcholine at muscarinic and nicotinic sites. Pyridostigmine is used for symptomatic treatment of myasthenia gravis. Physostigmine enters the CNS; its use in selected antimuscarinic toxicity requires specialist assessment because contraindications matter.
03
Muscarinic antagonists
Atropine blocks muscarinic effects, increasing heart rate in susceptible bradycardic states and reducing secretions. Ipratropium and tiotropium reduce cholinergic bronchoconstriction. Oxybutynin reduces bladder urgency but can produce dry mouth, constipation, blurred vision and cognitive effects. Antimuscarinic exposure can cause urinary retention and may precipitate angle closure in predisposed eyes. Central toxicity includes agitation and delirium, not simply sleepiness.
04
Organophosphates and cholinergic excess
Organophosphates inhibit acetylcholinesterase and can cause bronchorrhea, bronchospasm, bradycardia, diarrhea, miosis, fasciculations and weakness. Airway and ventilatory support are central to emergency management. Atropine treats muscarinic manifestations but does not reverse neuromuscular paralysis. Oximes may reactivate the inhibited enzyme before aging, depending on the agent and timing. Decontamination and antidote decisions belong to supervised emergency protocols; this mechanism summary is not a complete poisoning algorithm.
05
Neuromuscular blockers and ganglia
Rocuronium competitively blocks muscular nicotinic receptors. Succinylcholine depolarizes the end plate and can cause hyperkalemia in susceptible states or trigger malignant hyperthermia. Reduced plasma cholinesterase activity can prolong succinylcholine paralysis. Neuromuscular blockers provide neither analgesia nor unconsciousness, so anesthesia and ventilation are essential. Ganglion blockers affect both autonomic divisions; the net organ response depends on the dominant resting tone, which explains their broad and often limiting adverse effects.
High-Yield Revision
- Atropine blocks muscarinic receptors; it does not reverse nicotinic paralysis.
- Paralysis is not anesthesia or analgesia.
- Sweat glands are sympathetically innervated but use muscarinic signaling.
Common Exam & Concept Pitfalls
- Exclude mechanical obstruction before stimulating bladder or gut contraction.
- Do not assume all cholinesterase inhibitors enter the CNS equally.
Sources & Further Reading
Curriculum scope checked 23 September 2026. These original study notes summarize established principles; current institutional guidance and product information govern clinical use. Faculty review is pending.
RAHBAR study structure: target → drug action → therapeutic use → adverse effects → monitoring. Use institutional curriculum and faculty guidance for local sequencing, practical requirements and assessment specifications.